Metformin and breast cancer risk: A meta-analysis and critical literature review

Breast Cancer Research and Treatment

Volumn 135, Issue 3, 2012, Pages 639-646

  Col, Nananda F ^a,b   Ochs, Leslie ^a   Springmann, Vicky ^c   Aragaki, Aaron K ^d   Chlebowski, Rowan T ^e  

^a UNIVERSITY OF NEW ENGLAND   (United States)

^b Shared Decision Making Resources   (United States)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d Fred Hutchinson Cancer Research Center   (United States)

^e HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Literature review; Meta analyses; Metformin

Indexed keywords

INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; SULFONYLUREA;

BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CANCER SPECIFIC SURVIVAL; COHORT ANALYSIS; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG USE; HUMAN; INSULIN TREATMENT; META ANALYSIS; OBSERVATIONAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTECTION; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

BREAST NEOPLASMS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; POSTMENOPAUSE; RISK FACTORS;

EID: 84866548333     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2170-x     Document Type: Review

References (45)

1. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body mass index and incidence of cancer: a systemic review and meta-analyses of prospective observational studies. Lancet 371: 569-578 (Pubitemid 351232031)
2. Hvidtfeldt UA, Gunter MJ, Lange T et al (2012) Quantifying mediating effects of endogenous estrogen and insulin in the relation between obesity, alcohol consumption and breast cancer. Cancer Epidemiol Biomarkers Prev. May 7 [Epub ahead of print]
3. Wolf I, Sadetzki S, Catane R et al (2005) Diabetes mellitus and breast cancer. Lancet Oncol 6:103-111 (Pubitemid 40197704)
4. Larsson SC, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 121:856-862 (Pubitemid 47106217)
5. Cohen H, Letoith D (2012) Obesity, type 2 diabetes and cancer: the insulin and insulin-like growth factor connection. Endocr Relat Cancer. May 16 [Epub ahead of print]
6. Nathan DM, Buse JB, Davidson MB et al (2009) Medical management of hyperglycemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52:17-30
7. Goodwin PJ, Pritchard KI, Ennis M et al (2008) Insulin lowering effects of metformin in women with early breast cancer. Clin Breast Cancer 8:501-505
8. Gonzalez-Angulo AM, Meric-Bernstam F (2010) Metformin a therapeutic opportunity in breast cancer. Clin Cancer Res 16:1695-1700
9. Zhou G, Myers R, Li et al (2001) Role of AMP-activated protein kinase mechanism of metformin action. J Clin Invest 108:1167-1174 (Pubitemid 32995375)
10. DeCensi A, Puntoni M, Goodwin PJ et al (2010) Metformin and cancer risk in diabetic patients: a systematic review and metaanalysis. Cancer Prev Res 3:1451-1461
11. Currie CJ, Poole CD, Gale EA (2009) The influence of glucoselowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766-1777
12. Libby G, Donnelly LA, Donnan PT et al (2009) New users of metformin are at low risk of incident cancer. Diabetes Care 32:1620-1625
13. Bodmer M, Meier C, Krahenbuhl S et al (2010) Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33:1304-1308
14. Noto H, Goto A, Tsujimoto T, Noda M (2012) Cancer risk in diabetic patients treated with metformin: a systemic review and meta-analysis. PLoS One 7:e33411
15. Peairs KS, Barone BB, Snyder CF et al (2011) Diabetes mellitus and breast cancer outcomes: a systematic review and metaanalysis. J Clin Oncol 29:40-46
16. Guyatt GH, Oxman AD, Vist G et al (2011) GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias). J Clin Epidemiology 64:407-415
17. Monami M, Colombi C, Balzi D et al (2011) Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 34:129-131
18. Yang X, So WY, Ma RCW et al (2011) Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes. Diabetes Care 34:375-380
19. Bo S, Benso A, Durazzo M, Ghigo E (2012) Does use of metformin protect against cancer in type 2 diabetes mellitus? J Endocrinol Invest 35:231-232
20. Yang X, So WY, Ma RC et al (2012) Diabetes and cancer: the mechanistic implications of epidemiological analyses from the Hong Kong Diabetes Registry. Diabetes Metab Res Rev. Feb 8 [Epub ahead of print]
21. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R et al (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373:2125-2135
22. Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H et al (2010) Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 53:1838-1845
23. Morden NE, Liu SK, Smith J, Mackenzie TA, Skinner J et al (2011) Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care 34:1965-1971
24. Bayraktar S, Hernadez-Aya LF, Lei X et al (2012) Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 118:1202-1211
25. Staa Van, Patel D, Gallagher AM, de Bruin ML (2012) Glucoselowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. Diabetologia 55:654-665
26. Chlebowski RT, McTiernan A, Wactawski-Wende J et al (2012) Diabetes, metformin and breast cancer in postmenopausal women. J Clin Oncol. doi:10.1200/JCO.2011.39.7505
27. Bosco JLF, Antonsen S, Sorensen HT et al (2011) Metformin and incident breast cancer among diabetic women: a populationbased case-control study in Denmark. Cancer Epidemiol Biomarkers Prev 20:101-111
28. Bodmer M, Meier C, Krahenbuhl S et al (2012) Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33:1304-1308
29. Ruitter R, Visser LE, Van Herk-Sukel MPP et al (2012) Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives. Diabetes Care 35:119-1243
30. Dowling RJ, Niraula S, Stambolic V, Goodwin PJ (2012) Metformin in cancer: translational challenges. J Mol Endocrinol 48:R31-R43
31. Hadad S, Iwamoto T, Jordan L et al (2011) Evidence for biological effects of metformin in operable breast cancer: a preoperative, window-of-opportunity, randomized trial. Breast Cancer Rest Treat. Jun 8 [Epub ahead of print]
32. Bonanni B, Puntoni M, Cazzaniga M et al (2012) Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol. May 7 [Epub ahead of print]
33. Yerushalmi R, Woods R, Ravdin PM et al (2010) Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11: 174-183
34. Jiralerspong S, Palla SL, Giordano SH et al (2009) Metformin and pathologic complete response to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27:3297-3302
35. He X, Esteva FJ, Ensor J et al (2011) Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2 ? breast cancer. Ann Oncol. Nov 22 [Epub ahead of print]
36. Alimova IN, Liu B, Fan Z et al (2009) Metformin inhibits breast cancer cell growth, colony formation and reduces cell cycle arrest in vitro. Cell Cycle 8:909-915
37. Ben-Sahra I, Regazzetti C, Robert C et al (2011) Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. Jun 28 [epub ahead of print]
38. Martin M, Marais R (2012) Metformin: a diabetes drug for cancer, or a cancer drug for diabetes?. J Clin Oncol. May7 [Epub ahead of print]
39. Bachelot T, Bourgier C, Cropet C et al (2012) Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 002-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. May 7 [Epub ahead of print]
40. Baselga J, Campone M, Piccart M et al (2012) Everolimus in postmenopausal hormone receptor-positive advanced breast cancer. N Engl J Med 366:520-529
41. Liu H, Scholz C, Zang C et al (2012) Metformin and the mTOR Inhibitor Everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Anticancer Res 32:1627-1637
42. Tahrani AA, Bailey CJ, Del Prato S, Barnett AH (2011) Management of type 2 diabetes: new and future developments in treatment. Lancet 378:182-197
43. Yang X, So WY, Ma RC et al (2012) Use of thiazolidinedione and cancer risk in type 2 diabetes: the Hong Kong diabetes registry. Diabetes Res Clin PRact. Apr 11 [Epub ahead of print]
44. Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology (MOOSE) group l (a proposal for reporting). JAMA 283:2008-2012 (Pubitemid 30214957)
45. Goodwin PJ, Stambolic V, Lemieux J et al (2011) Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 126:215-220